Patent Application
20140315882
This invention relates to new compounds, in particular pyrimidine-substituted pyrrolidine derivatives, to processes for preparing such compounds, to their use as inhibitors of acetyl-CoA carboxylase(s), to methods for their therapeutic use, in particular in diseases and conditions mediated by the inhibition of acetyl-CoA carboxylase(s), and to pharmaceutical compositions comprising them.
Obesity is a major public health issue not only for the EU, USA, Japan but also for the world in general. It is associated with a number of serious diseases including diabetes, dyslipidemia, hypertension, cardiovascular and cerebrovascular diseases. Although the underlying mechanisms are not yet fully understood, the impairement of insulin action in target tissues by accumulation of excess lipids is generally regarded as a key mechanism linking obesity to secondary pathologies (G. Wolf, Nutrition Reviews Vol. 66(10):597-600; D B Savage, K F Petersen, G I Shulman, Physiol Rev. 2007; 87:507-520). Therefore, understanding of cellular lipid metabolism in insulin target tissues is crucial in order to elucidate the development of diseases associated with obesity.
A central event in lipid metabolism is the generation of malonyl-CoA via carboxylation of acetyl-CoA by the two mammalian ACC isoforms ACC1 (ACC-alpha, also termed ACCA) and ACC2 (ACC-beta, also designated ACCB) (Saggerson D. Annu Rev Nutr. 2008; 28:253-72). The malonyl-CoA generated is used for de novo fatty acid synthesis and acts as inhibitor of CPT-1, thereby regulating mitochondrial fatty acid oxidation. Furthermore, malonyl-CoA is also described to act centrally to control food intake, and may play an important role in controlling insulin secretion from the pancreas (G D Lopaschuk, J R Ussher, J S Jaswal. Pharmacol Rev. 2010; 62(2):237-64; D Saggerson Annu Rev Nutr. 2008; 28:253-72), further coordinating the regulation of intermediary metabolism.
Therefore ACC1 and ACC2 have been shown to be major regulators of fatty acid metabolism and are presently considered as an attractive target to regulate the human diseases of obesity, diabetes and cardiovascular complications (S J Wakil and L A Abu-Elheiga, J. Lipid Res. 2009. 50: S138-S143; L. Tong, H J Harwood Jr. Journal of Cellular Biochemistry 99:1476-1488, 2006).
As a result of its unique position in intermediary metabolism, inhibition of ACC offers the ability to inhibit de novo fatty acid production in lipogenic tissues (liver and adipose) while at the same time stimulating fatty acid oxidation in oxidative tissues (liver, heart, and skeletal muscle) and therefore offers an attractive modality for favorably affecting, in a concerted manner, a multitude of cardiovascular risk factors associated with obesity, diabetes, insulin resistance, nonalcoholic steatohepatitis (NASH) and the metabolic syndrome (L. Tong, H J Harwood Jr. Journal of Cellular Biochemistry 99:1476-1488, 2006; Corbett J W, Harwood J H Jr., Recent Pat Cardiovasc Drug Discov. 2007 November; 2(3):162-80).
Furthermore recent data show that cellular toxicity mediated by lipids (lipotoxicity) is implicated in the susceptibitlity to diabetes associated nephropathy (for review see M Murea, B I Freedmann, J S Parks, P A Antinozzi, S C Elbein, L M Ma; Clin J Am Soc Nephrol. 2010; 5:2373-9). A large-scale genome-wide association study in japanese patients identified single nucleotide polymorphism in the ACC2 gene (ACACB) associated with diabetic nephropathy risk which was replicated in nine independent cohorts. In the kidney, dysregulation of fatty acid metabolism leading to increased fatty acid levels is believed to lead to glomerular and tubular dysfunction (M Murea, B I Freedmann, J S Parks, P A Antinozzi, S C Elbein, L M Ma; Clin J Am Soc Nephrol. 2010; 5:2373-9). Therefore inhibitors targeting ACC as key molecule involved in lipid oxidation have the potential to be beneficial for favorably affecting diabetic nephropathy.
Additionally, insulin resistance, deregulated lipid metabolism, lipotoxicity and increased intramuscular lipids have also been described to play a role in type 1 diabetes (I E Schauer, J K Snell-Bergeon, B C Bergman, D M Maahs, A Kretowski, R H Eckel, M Rewers Diabetes 2011; 60:306-14; P Ebeling, B Essén-Gustaysson, J A Tuominen and V A Koivisto Diabetologia 41: 111-115; K J Nadeau, J G Regensteiner, T A Bauer, M S Brown, J L Dorosz, A Hull, P Zeitler, B Draznin, J E B. Reusch J Clin Endocrinol Metab, 2010, 95:513-521). Therefore ACC inhibitors are also considered as interesting drugs for the treatment of type 1 diabetes.
In addition ACC inhibitors also have the potential to intervene in the progression of diseases that result from the rapid growth of malignant cells or invading organisms that are dependent on endogenous lipid synthesis to sustain their rapid proliferation. De novo lipogenesis is known to be required for growth of many tumor cells and ACC up-regulation has been recognized in multiple human cancers, promoting lipogenesis to meet the need of cancer cells for rapid growth and proliferation (C Wang, S Rajput, K Watabe, D F Liao, D Cao Front Biosci 2010; 2:515-26). This is further demonstrated in studies using ACC inhibitors which induced growth arrest and selective cytotoxicity in cancer cells and by RNA interference-mediated knock-down of ACC which inhibited growth and induced apoptosis in different types of cancer cells. Furthermore, ACC1 associates with and is regulated by the breast cancer susceptibility gene 1 (BRCA1). Commonly occurring BRCA1 mutations lead to ACC1 activation and breast cancer susceptibility (C Wang, S Rajput, K Watabe, D F Liao, D Cao Front Biosci 2010; 2:515-26).
Furthermore in central nervous system disorders including but not limited to Alzheimer's disease, Parkinson disease and epilepsy, impairements in neuronal energy metabolism have been described (Ogawa M, Fukuyama H, Ouchi Y, Yamauchi H, Kimura J, J Neurol Sci. 1996; 139(1):78-82). Interventions targeting this metabolic defect may prove beneficial to the patients. One promising intervention is therefore to provide the glucose-compromised neuronscerebral brain neurons with ketone bodies as an alternative substrate (ST Henderson Neurotherapeutics, 2008, 5:470-480; L C Costantini, L J Barr, J L Vogel, S T Henderson BMC Neurosci. 2008, 9 Suppl 2:S16; KW Barañano, A L Hartman. Curr Treat Options Neurol. 2008; 10:410-9). ACC inhibition leading to increased fatty acid oxidation may thereby result in increases in the blood levels of ketone bodies thereby providing an alternative energy substrate for the brain.
Preclinical and clinical evidence indicates that ketone bodies can provide neuroprotective effects in models of Parkinson's disease, AD, hypoxia, ischemia, amyotrophic lateral sclerosis and glioma (L C Costantini, L J Barr, J L Vogel, S T Henderson BMC Neurosci. 2008, 9 Suppl 2:S16) and improved cognitive scores in Alzheimers Diseases patients (M A Reger, S T Henderson, C Hale, B Cholerton, L D Baker, G S Watson, K Hydea, D Chapmana, S Craft Neurobiology of Aging 25 (2004) 311-314). The end result of increased ketone levels is an improvement in mitochondrial efficiency and reduction in the generation of reactive oxygen species (for reviews see L C Costantini, L J Barr, J L Vogel, S T Henderson BMC Neurosci. 2008, 9 Suppl 2:S16; K W Baranano, A L Hartman. Curr Treat Options Neurol. 2008; 10:410-9).
Furthermore, the potential of ACC inhibitors as antifungal agents and as antibacterial agents is well documented (L. Tong, H J Harwood Jr. Journal of Cellular Biochemistry 99:1476-1488, 2006). In addition, ACC inhibitors can be used to combat viral infections. It was discovered recently that viruses rely on the metabolic network of their cellular hosts to provide energy and building blocks for viral replication (Munger J, B D Bennett, A Parikh, X J Feng, J McArdle, H A Rabitz, T Shenk, J D Rabinowitz. Nat. Biotechnol. 2008; 26:1179-86). A flux measurement approach to quantify changes in metabolic activity induced by human cytomegalovirus (HCMV) elucidated that infection with HCMV markedly changed fluxes through much of the central carbon metabolism, including glycolysis, tricarboxylic acid cycle and fatty acid biosynthesis. Pharmacological inhibition of fatty acid biosynthesis suppressed the replication of two divergent enveloped viruses (HCMV and influenza A) indicating that fatty acid synthesis is essential for the replication. These examples show that acetyl-CoA fluxes and de novo fatty acid biosynthesis are critical to viral survival and propagation as the newly synthesized fatty acids and phospholipids are important for formation of viral envelopes. Changing the metabolic flux influences the absolute quantity of phospholipid available, the chemical composition and physical properties of the envelope negatively affect viral growth and replication. Hence, ACC inhibitors acting on key enzymes in the fatty acid metabolism, have the potential to be antiviral drugs.
The aim of the present invention is to provide new compounds, in particular new pyrrolidine derivatives, which are active with regard to acetyl-CoA carboxylase(s).
Another aim of the present invention is to provide new compounds, in particular new pyrrolidine derivatives, which are active with regard to ACC2.
A further aim of the present invention is to provide new compounds, in particular new pyrrolidine derivatives, which have an inhibitory effect on acetyl-CoA carboxylase(s) in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
A further aim of the present invention is to provide new compounds, in particular new pyrrolidine derivatives, which have an inhibitory effect on ACC2 in vitro and/or in vivo and possess suitable pharmacological and pharmacokinetic properties to use them as medicaments.
A further aim of the present invention is to provide effective ACC inhibitors, in particular for the treatment of metabolic disorders, for example of obesity and/or diabetes.
A further aim of the present invention is to provide methods for treating a disease or condition mediated by the inhibition of acetyl-CoA carboxylase(s) in a patient.
A further aim of the present invention is to provide a pharmaceutical composition comprising at least one compound according to the invention.
A further aim of the present invention is to provide a combination of at least one compound according to the invention with one or more additional therapeutic agents.
A further aim of the present invention is to provide methods for the synthesis of the new compounds, in particular pyrrolidine derivatives.
A further aim of the present invention is to provide starting and/or intermediate compounds suitable in methods for the synthesis of the new compounds.
Further aims of the present invention become apparent to the one skilled in the art by the description hereinbefore and in the following and by the examples.
Within the scope of the present invention it has now surprisingly been found that the new compounds of general formula (I) as described hereinafter exhibit an inhibiting activity with regard to acetyl-CoA carboxylase(s).
According to another aspect of the present invention it has been found that the new compounds of general formula (I) as described hereinafter exhibit an inhibiting activity with regard to ACC2.
In a first aspect the present invention provides a compound of general formula
wherein
In a further aspect the present invention relates to processes for preparing a compound of general formula (I) and to new intermediate compounds in these processes.
A further aspect of the invention relates to a salt of the compounds of general formula (I) according to this invention, in particular to a pharmaceutically acceptable salt thereof.
In a further aspect this invention relates to a pharmaceutical composition, comprising one or more compounds of general formula (I) or one or more pharmaceutically acceptable salts thereof according to the invention, optionally together with one or more inert carriers and/or diluents.
In a further aspect this invention relates to a method for treating diseases or conditions which are mediated by inhibiting the activity of acetyl-CoA carboxylase(s) in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
According to another aspect of the invention, there is provided a method for treating a metabolic disease or disorder in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
According to another aspect of the invention, there is provided a method for treating a cardiovascular disease or disorder in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
According to another aspect of the invention, there is provided a method for treating a neurodegenerative disease or disorder or for treating a disease or disorder of the central nervous system in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
According to another aspect of the invention, there is provided a method for treating a cancer, a malignant disorder or a neoplasia in a patient in need thereof characterized in that a compound of general formula (I) or a pharmaceutically acceptable salt thereof is administered to the patient.
According to another aspect of the invention, there is provided the use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for a therapeutic method as described hereinbefore and hereinafter.
According to another aspect of the invention, there is provided a compound of the general formula (I) or a pharmaceutically acceptable salt thereof for a therapeutic method as described hereinbefore and hereinafter.
In a further aspect this invention relates to a method for treating a disease or condition mediated by the inhibition of acetyl-CoA carboxylase(s) in a patient that includes the step of administering to the patient in need of such treatment a therapeutically effective amount of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of one or more additional therapeutic agents.
In a further aspect this invention relates to a use of a compound of the general formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents for the treatment or prevention of diseases or conditions which are mediated by the inhibition of acetyl-CoA carboxylase(s).
In a further aspect this invention relates to a pharmaceutical composition which comprises a compound according to general formula (I) or a pharmaceutically acceptable salt thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.
Other aspects of the invention become apparent to the one skilled in the art from the specification and the experimental part as described hereinbefore and hereinafter.
Unless otherwise stated, the groups, residues, and substituents, particularly Ar, R1, R2, R3, R4, L, T and n, are defined as above and hereinafter. If residues, substituents, or groups occur several times in a compound, as for example R1, they may have the same or different meanings. Some preferred meanings of individual groups and substituents of the compounds according to the invention will be given hereinafter. Any and each of these definitions may be combined with each other.
The group Ar is preferably selected from the group Ar-G1 as defined hereinbefore and hereinafter.
In another embodiment the group Ar is selected from the group Ar-G2 consisting of: phenylene, which is optionally monosubstituted with F.
In another embodiment the group Ar is selected from the group Ar-G3 consisting of: phenylene.
In another embodiment the group Ar is selected from the group Ar-G4 consisting of:
wherein the before mentioned group is optionally monosubstituted with F.
In another embodiment the group Ar is selected from the group Ar-G5 consisting of:
The group R1 is preferably selected from the group R1-G1 as defined hereinbefore and hereinafter.
In another embodiment the group R1 is independently of one another selected from the group R1-G2 consisting of:
F, Cl, Br, CN, C1-4-alkyl, C3-6-cycloalkyl, phenyl, —O—(C1-5-alkyl), —O—(C3-6-cycloalkyl), —O—(C5-6-cycloalkenyl), —O—(CH2)1-2—(C3-6-cycloalkyl), —O—(C1-2-alkyl)-phenyl, —O—CH2—(C2-4-alkenyl), —O—CH2-heterocyclyl, —O—CH2-pyridinyl, —O-heterocyclyl, —O-phenyl, —O-pyridinyl, —NRN1RN2 and
wherein RN1 is H, —CD3, or C1-3-alkyl, and
RN2 is —CD3, C1-5-alkyl, C3-6-cycloalkyl, —CH2—(C3-6-cycloalkyl), heterocyclyl, —CH2-heterocyclyl or phenyl,
or wherein RN1 and RN2 are connected and together with the N-atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, 2,5-dihydro-1H-pyrrolyl, morpholinyl, thiomorpholinyl or [1,4]oxazepanyl ring, wherein each of said rings is optionally substituted with one to four F or with one or two CN, OH, C1-3-alkyl, —O—C1-3-alkyl, or —C1-3-alkyl-O—C1-3-alkyl, said substituents being the same or different,
In another embodiment the group R1 is selected from the group R1-G3 consisting of: F, Cl, CN, C1-4-alkyl, C3-5-cycloalkyl, phenyl, —O—(C1-5-alkyl), —O—(C3-6-cycloalkyl), —O-tetrahydrofuranyl, —O—CH2—(C3-4-cycloalkyl), —NRN1RN2 and
wherein RN1 is H, —CD3, or C1-2-alkyl, and
RN2 is —CD3, C1-4-alkyl, C3-6-cycloalkyl, or —CH2—(C3-6-cycloalkyl),
or wherein RN1 and RN2 are connected and together with the N-atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl ring, wherein each of said rings is optionally substituted with one or two F, OH or CH3, said substituents being the same or different,
In another embodiment the group R1 is selected from the group R1-G4 consisting of: F, Cl, Br, CN, C1-4-alkyl, —O—(C1-5-alkyl), —O—(C3-6-cycloalkyl), —O-pyridinyl, —NRN1RN2,
wherein RN1 is H, —CD3 or C1-2-alkyl, and
RN2 is —CD3, C1-5-alkyl or C3-6-cycloalkyl,
In another embodiment the group R1 is selected from the group R1-G4a consisting of: C1-4-alkyl, —O—(C1-5-alkyl), —O—(C3-6-cycloalkyl), —O-pyridinyl, —NRN1RN2,
wherein RN1 is H, —CD3 or C1-2-alkyl, and
RN2 is —CD3, C1-5-alkyl or C3-6-cycloalkyl,
Preferably, n is 1 or 2.
In another embodiment the group R1 is selected from the group R1-G4b consisting of: —O—(C1-5-alkyl), —O—(C3-6-cycloalkyl), —O-pyridinyl, —NRN1RN2,
wherein RN1 is H, —CD3 or C1-2-alkyl, and
RN2 is —CD3, C1-5-alkyl or C3-6-cycloalkyl,
Preferably, n is 1 or 2.
In another embodiment the group R1 is selected from the group R1-G5 consisting of:
—O—(C1-5-alkyl), which is optionally substituted with 1-3 F or one OH;
—O—CH2—(C3-5-cycloalkyl), which is optionally substituted with 1-2 F;
—O—(C3-6-cycloalkyl);
—NRN1RN2, wherein RN2 is H or C1-2-alkyl; and RN2 is C1-4-alkyl or C3-6-cycloalkyl, wherein each alkyl is optionally substituted with 1 to 3 F or with one OH or —O—CH3;
In another embodiment the group R1 is selected from the group R1-G5a consisting of:
—O—(C1-5-alkyl), which is optionally substituted with 1-3 F or one OH;
—O—CH2—(C3-5-cycloalkyl), which is optionally substituted with 1-2 F;
—O—(C3-6-cycloalkyl);
—NRN1RN2, wherein RN1 is H or C1-2-alkyl; and RN2 is C1-4-alkyl or C3-6-cycloalkyl, wherein each alkyl is optionally substituted with 1 to 3 F or with one OH or —O—CH3;
or, if n is 2, the second R1 group is selected from the group consisting of F, Cl, Br, CN, CH3 and —O—CH3;
or, if n is 3, the third R1 group is F.
Preferably, n is 1 or 2.
In another embodiment the group R1 is selected from the group R1-G6 consisting of: F, Cl, —O—(C1-5-alkyl),
In another embodiment the group R1 is selected from the group R1-G6a consisting of: F, Cl, —O—(C1-5-alkyl),
or, if n is 2, the second R1 group is selected from the group consisting of F, Cl, Br, CN, CH3 and —O—CH3;
or, if n is 3, the third R1 group is F.
Preferably, n is 1 or 2.
n
n is 1, 2 or 3.
Preferably, n is 1 or 2.
In one embodiment, n is 2.
In another embodiment, n is 1.
The group R2 is preferably selected from the group R2-G1 as defined hereinbefore and hereinafter.
In another embodiment the group R2 is selected from the group R2-G2 consisting of: H, F and —O—CH3.
In another embodiment, the group R2 is selected from the group R2-G3 consisting of H.
The group R3 is preferably selected from the group R3-G1 as defined hereinbefore and hereinafter.
In one embodiment the group R3 is selected from the group R3-G2 consisting of H and CH3.
In another embodiment the group R3 is selected from the group R3-G3 consisting of H.
The group L is preferably selected from the group L-G1 as defined hereinbefore and hereinafter.
In one embodiment the group L is selected from the group L-G2 consisting of: a straight-chain C1-3-alkylene group which is optionally substituted with one or two CH3 groups.
In another embodiment the group L is selected from the group L-G3 consisting of: a straight-chain C1-2-alkylene group which is optionally substituted with one methyl group.
In another embodiment the group L is selected from the group L-G4 consisting of:
wherein m is 0 or 1, and
wherein the asterisk to the left-hand side is connected to Ar and the asterisk to the right-hand side is connected to N atom depicted in formula (I).
In another embodiment the group L is selected from the group L-G5 consisting of: —CH(CH3)—.
In another embodiment the group L is selected from the group L-G5a consisting of:
wherein the asterisk to the left-hand side is connected to Ar and the asterisk to the right-hand side is connected to N atom depicted in formula (I).
In another embodiment the group L is selected from the group L-G5b consisting of:
wherein the asterisk to the left-hand side is connected to Ar and the asterisk to the right-hand side is connected to N atom depicted in formula (I).
The group T is preferably selected from the group T-G1 as defined hereinbefore and hereinafter.
In one embodiment the group T is selected from the group T-G2 consisting of:
linear or branched C1-4-alkyl which is optionally substituted with one to six F, or with one CN, —O—CH3 or OH or with a heteroaryl group preferably selected from the group consisting of: oxazolyl, thiazolyl, pyrrolyl, isoxazolyl, pyrimidinyl and pyrazinyl,
In one embodiment the group T is selected from the group T-G3 consisting of:
linear or branched C1-3-alkyl which is optionally substituted with one to six F, or with one CN, OH or —O—CH3, or with a heteroaryl group preferably selected from the group consisting of thiazolyl, isoxazolyl and pyrimidinyl,
In one embodiment the group T is selected from the group T-G4 consisting of:
linear or branched C1-3-alkyl which is optionally substituted with one to three F,
C3-6-cycloalkyl which is optionally substituted with one F, CH3, —NH—(C═O)—CH3, —NH—(C═O)—CH2—O—CH3 or —NH—(C═O)—O—(C1-4-alkyl);
—O—(C1-2-alkyl) which is optionally substituted with one cyclopropyl;
—NR4R5, wherein R4 is H or C1-3-alkyl, and R5 is C1-3-alkyl or isoxazolyl; or wherein R4 and R5 are connected and together with the N to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl ring; and
A furanyl, thiazolyl, oxazolyl, pyrazolyl, isoxazolyl or isothiazolyl group, each of which is optionally substituted with one or two substituents selected independently from the group consisting of CH3, —NH—C(═O)—CH2—O—CH3, —NH—C(═O)—CH3 and —NH—C(═O)—CH2CH3.
In one embodiment the group T is selected from the group T-G4a consisting of:
linear or branched C1-3-alkyl which is optionally substituted with one to three F,
C3-6-cycloalkyl which is optionally substituted with one CH3, —NH—(C═O)—CH3, —NH—(C═O)—CH2—O—CH3 or —NH—(C═O)—O—(C1-4-alkyl);
—O—(C1-2-alkyl) which is optionally substituted with one cyclopropyl;
—NR4R5, wherein R4 is H or C1-3-alkyl, and R5 is C1-3-alkyl or isoxazolyl; or wherein R4 and R5 are connected and together with the N to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl ring; and
a thiazolyl, oxazolyl, pyrazolyl, isoxazolyl or isothiazolyl group, each of which is optionally substituted with one or two substituents selected independently from the group consisting of CH3, —NH—C(═O)—CH2—O—CH3 and —NH—C(═O)—CH3.
In one embodiment the group T is selected from the group T-G5 consisting of:
linear or branched C1-3-alkyl which is optionally substituted with one to three F;
—NH2, wherein each H is optionally independently of each other replaced with methyl or ethyl;
and
a 5-membered heteroaryl group selected from:
In one embodiment the group T is selected from the group T-G5a consisting of:
linear or branched C1-3-alkyl which is optionally substituted with one to three F;
—NH2, wherein each H is optionally independently of each other replaced with methyl or ethyl;
and
a 5-membered heteroaryl group selected from:
In one embodiment the group T is selected from the group T-G6 consisting of: —CH3, —CHF2, —CH2CH3, —N(CH3)2, —OCH3,
In one embodiment the group T is selected from the group T-G6a consisting of: —CH3, —CHF2, —CH2CH3, —N(CH3)2, —OCH3,
In one embodiment the group T is selected from the group T-G7 consisting of: CH3.
Examples of preferred subgeneric embodiments according to the present invention are set forth in the following table, wherein each substituent group of each embodiment is defined according to the definitions set forth hereinbefore and wherein all other substituents of the formula (I) are defined according to the definitions set forth hereinbefore:
The following preferred embodiments of compounds of the formula (I) are described using generic formulae (I.1a) to (I.4c), wherein any tautomers and stereoisomers, solvates, hydrates and salts thereof, in particular the pharmaceutically acceptable salts thereof, are encompassed.
wherein in each of the above formulae (I.1a) to (I.4c), the groups Ar, R1, R2, R3, L, T and n are defined as hereinbefore and hereinafter.
Examples of preferred subgeneric embodiments according to the present invention are set forth in the following table, wherein each substituent group of each embodiment is defined according to the definitions set forth hereinbefore and wherein all other substituents of the formula I are defined according to the definitions set forth hereinbefore:
A preferred embodiment of the present invention concerns compounds of general formula
wherein
n is 1 or 2 or 3;
R1 is selected from a group consisting of C1-4-alkyl, —O—(C1-5-alkyl), —O—(C3-6-cycloalkyl), —O-pyridinyl, —NRN1RN2,
wherein RN1 is H or C1-2-alkyl, and RN2 is C1-5-alkyl or C3-6-cycloalkyl,
T is selected from a group consisting of:
linear or branched C1-3-alkyl which is optionally substituted with one to three F,
C3-6-cycloalkyl which is optionally substituted with one F, CH3, —NH—(C═O)—CH3, —NH—(C═O)—CH2—O—CH3 or —NH—(C═O)—O—(C1-4-alkyl);
—O—(C1-2-alkyl) which is optionally substituted with one cyclopropyl;
—NR4R5, wherein R4 is H or C1-3-alkyl, and R5 is C1-3-alkyl or isoxazolyl; or wherein R4 and R5 are connected and together with the N to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl ring; and
a furanyl, thiazolyl, oxazolyl, pyrazolyl, isoxazolyl or isothiazolyl group, each of which is optionally substituted with one or two substituents selected independently from the group consisting of CH3, —NH—C(═O)—CH2—O—CH3, —NH—C(═O)—CH3 and —NH—C(═O)—CH2CH3;
or a salt thereof.
A preferred embodiment of the present invention concerns compounds of general formula
wherein
n is 1 or 2;
R1 is selected from a group consisting of:
—O—(C1-5-alkyl), which is optionally substituted with 1-3 F or one OH;
—O—CH2—(C3-5-cycloalkyl), which is optionally substituted with 1-2 F;
—O—(C3-6-cycloalkyl);
—NRN1RN2, wherein RN1 is H or C1-2-alkyl; and RN2 is —CD3, C1-4-alkyl or C3-6-cycloalkyl, wherein each alkyl is optionally substituted with 1 to 3 F or with one OH or —O—CH3;
or, if n is 2, the second R1 group is selected from the group consisting of F, Cl, Br, CN, CH3 and —O—CH3;
T is selected from a group consisting of:
or a pharmaceutically acceptable salt thereof.
Preferred compounds of the invention include:
and the pharmaceutically acceptable salts thereof.
Particularly preferred compounds, including their tautomers and stereoisomers, the salts thereof, or any solvates or hydrates thereof, are described in the experimental section hereinafter.
The compounds according to the invention may be obtained using methods of synthesis which are known to the one skilled in the art and described in the literature of organic synthesis. Preferably, the compounds are obtained analogously to the methods of preparation explained more fully hereinafter, in particular as described in the experimental section.
Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.
The terms “compound(s) according to this invention”, “compound(s) of formula (I)”, “compound(s) of the invention” and the like denote the compounds of the formula (I) according to the present invention including their tautomers, stereoisomers and mixtures thereof and the salts thereof, in particular the pharmaceutically acceptable salts thereof, and the solvates and hydrates of such compounds, including the solvates and hydrates of such tautomers, stereoisomers and salts thereof.
The terms “treatment” and “treating” embraces both preventative, i.e. prophylactic, or therapeutic, i.e. curative and/or palliative, treatment. Thus the terms “treatment” and “treating” comprise therapeutic treatment of patients having already developed said condition, in particular in manifest form. Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the conditions of the indication or to stop or slow down progression of the disease. Thus the compositions and methods of the present invention may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy. In addition the terms “treatment” and “treating” comprise prophylactic treatment, i.e. a treatment of patients at risk to develop a condition mentioned hereinbefore, thus reducing said risk.
When this invention refers to patients requiring treatment, it relates primarily to treatment in mammals, in particular humans.
The term “therapeutically effective amount” means an amount of a compound of the present invention that (i) treats or prevents the particular disease or condition, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or condition, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or condition described herein.
The terms “modulated” or “modulating”, or “modulate(s)”, as used herein, unless otherwise indicated, refers to the inhibition of acetyl-CoA carboxylase(s) (ACC) with one or more compounds of the present invention.
The terms “mediated” or “mediating” or “mediate”, as used herein, unless otherwise indicated, refers to the (i) treatment, including prevention the particular disease or condition, (ii) attenuation, amelioration, or elimination of one or more symptoms of the particular disease or condition, or (iii) prevention or delay of the onset of one or more symptoms of the particular disease or condition described herein.
The term “substituted” as used herein, means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound.
In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C1-6-alkyl means an alkyl group or radical having 1 to 6 carbon atoms. In general, for groups comprising two or more subgroups, the last named subgroup is the radical attachment point, for example, the substituent “aryl-C1-3-alkyl-” means an aryl group which is bound to a C1-3-alkyl-group, the latter of which is bound to the core or to the group to which the substituent is attached.
In case a compound of the present invention is depicted in form of a chemical name and as a formula in case of any discrepancy the formula shall prevail.
An asterisk is may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
The numeration of the atoms of a substituent starts with the atom which is closest to the core or to the group to which the substituent is attached.
For example, the term “3-carboxypropyl-group” represents the following substituent:
wherein the carboxy group is attached to the third carbon atom of the propyl group. The terms “1-methylpropyl-”, “2,2-dimethylpropyl-” or “cyclopropylmethyl-” group represent the following groups:
The asterisk may be used in sub-formulas to indicate the bond which is connected to the core molecule as defined.
In a definition of a group the term “wherein each X, Y and Z group is optionally substituted with” and the like denotes that each group X, each group Y and each group Z either each as a separate group or each as part of a composed group may be substituted as defined. For example a definition “Rex denotes H, C1-3-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl or C1-3-alkyl-O—, wherein each alkyl group is optionally substituted with one or more Lex.” or the like means that in each of the before mentioned groups which comprise the term alkyl, i.e. in each of the groups C1-3-alkyl, C3-6-cycloalkyl-C1-3-alkyl and C1-3-alkyl-O—, the alkyl moiety may be substituted with Lex as defined.
In the following the term bicyclic includes spirocyclic.
Unless specifically indicated, throughout the specification and the appended claims, a given chemical formula or name shall encompass tautomers and all stereo, optical and geometrical isomers (e.g. enantiomers, diastereomers, E/Z isomers etc. . . . ) and racemates thereof as well as mixtures in different proportions of the separate enantiomers, mixtures of diastereomers, or mixtures of any of the foregoing forms where such isomers and enantiomers exist, as well as salts, including pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates including solvates of the free compounds or solvates of a salt of the compound.
The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit/risk ratio.
As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a sufficient amount of the appropriate base or acid in water or in an organic diluent like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof.
Salts of other acids than those mentioned above which for example are useful for purifying or isolating the compounds of the present invention also comprise a part of the invention.
The term halogen generally denotes fluorine, chlorine, bromine and iodine.
The term “C1-n-alkyl”, wherein n is an integer from 1 to n, either alone or in combination with another radical denotes an acyclic, saturated, branched or linear hydrocarbon radical with 1 to n C atoms. For example the term C1-5-alkyl embraces the radicals H3C—, H3C—CH2—, H3C—CH2—CH2—, H3C—CH(CH3)—, H3C—CH2—CH2—CH2—, H3C—CH2—CH(CH3)—, H3C—CH(CH3)—CH2—, H3C—C(CH3)2—, H3C—CH2—CH2—CH2—CH2—, H3C—CH2—CH2—CH(CH3)—, H3C—CH2—CH(CH3)—CH2—, H3C—CH(CH3)—CH2—CH2—, H3C—CH2—C(CH3)2—, H3C—C(CH3)2—CH2—, H3C—CH(CH3)—CH(CH3)— and H3C—CH2—CH(CH2CH3)—.
The term “C1-n-alkylene” wherein n is an integer 1 to n, either alone or in combination with another radical, denotes an acyclic, straight or branched chain divalent alkyl radical containing from 1 to n carbon atoms. For example the term C1-4-alkylene includes —(CH2)—, —(CH2—CH2)—, —(CH(CH3))—, —(CH2—CH2—CH2)—, —(C(CH3)2)—, —(CH(CH2CH3))—, —(CH(CH3)—CH2)—, —(CH2—CH(CH3))—, —(CH2—CH2—CH2—CH2)—, —(CH2—CH2—CH(CH3))—, —(CH(CH3)—CH2—CH2)—, —(CH2—CH(CH3)—CH2)—, —(CH2—C(CH3)2)—, —(C(CH3)2—CH2)—, —(CH(CH3)—CH(CH3))—, —(CH2—CH(CH2CH3))—, —(CH(CH2CH3)—CH2)—, —(CH(CH2CH2CH3))—, —(CHCH(CH3)2)- and —C(CH3)(CH2CH3)—.
The term “C2-n-alkenyl”, is used for a group as defined in the definition for “C1-n-alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond. For example the term C2-3-alkenyl includes —CH═CH2, —CH═CH—CH3, —CH2—CH═CH2.
The term “C2-n-alkenylene” is used for a group as defined in the definition for “C1-n-alkylene” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a double bond. For example the term C2-3-alkenylene includes —CH═CH—, —CH═CH—CH2—, —CH2—CH═CH—.
The term “C2-n-alkynyl”, is used for a group as defined in the definition for “C1-n-alkyl” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond. For example the term C2-3-alkynyl includes —C≡CH, —C≡C—CH3, —CH2—C≡CH.
The term “C2-n-alkynylene” is used for a group as defined in the definition for “C1-n-alkylene” with at least two carbon atoms, if at least two of those carbon atoms of said group are bonded to each other by a triple bond. For example the term C2-3-alkynylene includes —C≡C—, —C≡C—CH2—, —CH2—C≡C—.
The term “C3-n-carbocyclyl” as used either alone or in combination with another radical, denotes a monocyclic, bicyclic or tricyclic, saturated or unsaturated hydrocarbon radical with 3 to n C atoms. The hydrocarbon radical is preferably nonaromatic. Preferably the 3 to n C atoms form one or two rings. In case of a bicyclic or tricyclic ring system the rings may be attached to each other via a single bond or may be fused or may form a spirocyclic or bridged ring system. For example the term C3-10-carbocyclyl includes C3-10-cylcoalkyl, C3-10-cycloalkenyl, octahydro-pentalenyl, octahydroindenyl, decahydronaphthyl, indanyl, tetrahydronaphthyl. Most preferably, the term C3-n-carbocyclyldenotes C3-n-cylcoalkyl, in particular C3-7-cycloalkyl.
The term “C3-n-cycloalkyl”, wherein n is an integer 4 to n, either alone or in combination with another radical denotes a cyclic, saturated, unbranched hydrocarbon radical with 3 to n C atoms. The cyclic group may be mono-, bi-, tri- or spirocyclic, most preferably monocyclic. Examples of such cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclododecyl, bicyclo[3.2.1]octyl, spiro[4.5]decyl, norpinyl, norbonyl, norcaryl, adamantyl, etc.
The term “C3-n-cycloalkenyl”, wherein n is an integer 3 to n, either alone or in combination with another radical, denotes a cyclic, unsaturated but nonaromatic, unbranched hydrocarbon radical with 3 to n C atoms, at least two of which are bonded to each other by a double bond. For example the term C3-7-cycloalkenyl includes cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cycloheptenyl, cycloheptadienyl and cycloheptatrienyl.
The term “aryl” as used herein, either alone or in combination with another radical, denotes a carbocyclic aromatic monocyclic group containing 6 carbon atoms which may be further fused to a second 5- or 6-membered carbocyclic group which may be aromatic, saturated or unsaturated. Aryl includes, but is not limited to, phenyl, indanyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl. More preferably, the term “aryl” as used herein, either alone or in combination with another radical, denotes phenyl or naphthyl, most preferably phenyl.
The term “heterocyclyl” means a saturated or unsaturated mono-, bi-, tri- or spirocarbocyclic, preferably mono-, bi- or spirocyclic-ring system containing one or more heteroatoms selected from N, O or S(O)r with r=0, 1 or 2, which in addition may have a carbonyl group. More preferably, the term “heterocyclyl” as used herein, either alone or in combination with another radical, means a saturated or unsaturated, even more preferably, a saturated mono-, bi- or spirocyclic-ring system containing 1, 2, 3 or 4 heteroatoms selected from N, O or S(O)r with r=0, 1 or 2 which in addition may have a carbonyl group. The term “heterocyclyl is intended to include all the possible isomeric forms. Examples of such groups include aziridinyl, oxiranyl, azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, azepanyl, piperazinyl, morpholinyl, tetrahydrofuranonyl, tetrahydropyranonyl, pyrrolidinonyl, piperidinonyl, piperazinonyl, morpholinonyl.
Thus, the term “heterocyclyl” includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
The term “heteroaryl” means a mono- or polycyclic, preferably mono- or bicyclic-ring system containing one or more heteroatoms selected from N, O or S(O)r with r=0, 1 or 2 wherein at least one of the heteroatoms is part of an aromatic ring, and wherein said ring system may have a carbonyl group. More preferably, the term “heteroaryl” as used herein, either alone or in combination with another radical, means a mono- or bicyclic-ring system containing 1, 2, 3 or 4 heteroatoms selected from N, O or S(O)r with r=0, 1 or 2 wherein at least one of the heteroatoms is part of an aromatic ring, and wherein said ring system may have a carbonyl group. The term “heteroaryl” is intended to include all the possible isomeric forms.
Thus, the term “heteroaryl” includes the following exemplary structures which are not depicted as radicals as each form may be attached through a covalent bond to any atom so long as appropriate valences are maintained:
Many of the terms given above may be used repeatedly in the definition of a formula or group and in each case have one of the meanings given above, independently of one another.
All rests and substituents as defined hereinbefore and hereinafter may be substituted with one or more F atoms.
The activity of the compounds of the invention may be demonstrated using the following ACC2 assay:
Malonyl CoA formation by acetyl CoA carboxylases is stoichometrically linked to the consumption of ATP. ACC2 activity is measured in a NADH-linked kinetic method measuring ADP generated during the ACC reaction using a coupled lactate dehydrogenase/pyruvate kinase reaction.
For biological testing, a human ACC2 construct which lacks the 128 amino acids at the N-terminus for increased solubility (nt 385-6966 in Genbank entry AJ575592) is cloned. The protein is then expressed in insect cells using a baculoviral expression system. Protein purification is performed by anion exchange.
All compounds are dissolved in dimethyl sulfoxide (DMSO) to a concentration of 10 mM.
Assay reactions are then carried out in 384-well plates, with hACC2 in an appropriate dilution and at final assay concentrations (f.c.) of 100 mM Tris (pH 7.5), 10 mM trisodium citrate, 25 mM KHCO3, 10 mM MgCl2, 0.5 mg/ml BSA, 3.75 mM reduced L-glutathione, 15 U/ml lactate dehydrogenase, 0.5 mM phosphoenolpyruvate, 15 U/ml pyruvate kinase, compounds at different concentrations at final DMSO concentrations of 1%.
The enzymatic reaction is then started by addition of a mixture of NADH, acetyl Coenzyme A (both 200 μM f.c.) and ATP (500 uM f.c.). The decrease of the optical density (slope S) is then determined at 25° C. at a wavelength of 340 nm over 15 minutes in a spectrophotometric reader.
Each assay microtiter plate contains wells with vehicle instead of compound as controls for the non-inhibited enzyme (100% CTL; ‘HIGH’) and wells without acetyl-CoA as controls for non-specific NADH degradation (0% CTL; ‘LOW’).
The slope S is used for calculation of % CTL=(S(compound)−S(‘LOW’))/(S(‘HIGH’)−S(‘LOW’))*100. Compounds will give values between 100% CTL (no inhibition) and 0% CTL (complete inhibition).
For IC50 value determination, the sample slope in the presence of the test compound after subtraction of the low controls (S(compound)−S(‘LOW’)) are used.
An IC50 value is derived from the compound slopes at different dosages after subtraction of the low controls (S(compound)−S(‘LOW’)) by non-linear regression curve fitting (equation y=(A+((B−A)/(1+((C/x)̂D))))).
The compounds of general formula (I) according to the invention for example have IC50 values below 5000 nM, particularly below 1000 nM, preferably below 300 nM, most preferably below 100 nM.
In the following table the activity expressed as IC50 (μM) of compounds according to the invention is presented wherein the IC50 values are determined in the ACC2 assay as described hereinbefore. The term “Example” refers to the example numbers according to the following experimental section.
In view of their ability to inhibit acetyl-CoA carboxylase(s), the compounds of general formula (I) according to the invention and the corresponding salts thereof are theoretically suitable for the treatment, including preventative treatment of all those diseases or conditions which may be affected or which are mediated by the inhibition of acetyl-CoA carboxylase(s), in particular ACC2, activity.
Accordingly, the present invention relates to a compound of general formula (I) as a medicament.
Furthermore, the present invention relates to the use of a compound of general formula (I) for the treatment and/or prevention of diseases or conditions which are mediated by the inhibition of acetyl-CoA carboxylase(s), in particular ACC2, in a patient, preferably in a human.
In yet another aspect the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of acetyl-CoA carboxylase(s) in a mammal that includes the step of administering to a patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention, or a pharmaceutical composition thereof.
Diseases and conditions mediated by inhibitors of acetyl-CoA carboxylases embrace metabolic and/or cardiovascular and/or neurodegenerative diseases or conditions.
According to one aspect the compounds of the present invention are particularly suitable for treating diabetes mellitus, in particular Type 2 diabetes, Type 1 diabetes, and diabetes-related diseases, such as ishyperglycemia, metabolic syndrome, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, dyslipidemia, hypertension, hyperinsulinemia, and insulin resistance syndrome, hepatic insulin resistance, including complications such as macro- and microvascular disorders, including thromboses, hypercoagulable and prothrombotic states (arterial and venous), high blood pressure, coronary artery disease and heart failure, increased abdominal girth, hypercoagulability, hyperuricemia, micro-albuminemia.
According to another aspect the compounds of the present invention are particularly suitable for treating overweight, obesity, including visceral (abdominal) obesity, nonalcoholic fatty liver disease (NAFLD) and obesity related disorders, such as for example weight gain or weight maintenance.
Obesity and overweight are generally defined by body mass index (BMI), which is correlated with total body fat and estimates the relative risk of disease. BMI is calculated by weight in kilograms divided by height in meters squared (kg/m2). Overweight is typically defined as a BMI of 25-29.9 kg/m2, and obesity is typically defined as a BMI of 30 kg/m2 or greater.
According to another aspect the compounds of the present invention are particularly suitable for treating, including preventing, or delaying the progression or onset of diabetes or diabetes-related disorders including Type 1 (insulin-dependent diabetes mellitus, also referred to as “IDDM”) and Type 2 (noninsulin-dependent diabetes mellitus, also referred to as “NIDDM”) diabetes, impaired glucose tolerance, insulin resistance, hyperglycemia, pancreatic beta cell degeneration and diabetic complications (such as macro- and microvascular disorders, atherosclerosis, coronary heart disease, stroke, peripheral vascular disease, nephropathy, hypertension, neuropathy, and retinopathy).
In addition the compounds of the present invention are suitable for treating dyslipidemias in general and more specifically elevated lipid concentrations in the blood and in tissues, dysregulation of LDL, HDL and VLDL, in particular high plasma triglyceride concentrations, high postprandial plasma triglyceride concentrations, low HDL cholesterol concentration, low apoA lipoprotein concentrations, high LDL cholesterol concentrations, high apoB lipoprotein concentrations, including atherosclerosis, coronary heart disease, cerebrovascular disorders, diabetes mellitus, metabolic syndrome, obesity, insulin resistance and/or cardiovascular disorders.
ACC inhibition may lead to a centrally stimulating effect on food intake. Therefore compounds of the present invention may be suitable for treating eating disorders such as anorexia nervosa.
In addition the compounds of the present invention may provide neuroprotective effects in patients with Parkinson's disease, Alzheimer's disease, hypoxia, ischemia, amyotrophic lateral sclerosis or glioma and may improve cognitive scores in Alzheimer's diseases patients.
Further diseases and conditions mediated by inhibitors of acetyl-CoA carboxylases embrace but are not limited to:
The dose range of the compounds of general formula (I) applicable per day is usually from 0.001 to 10 mg per kg body weight of the patient, preferably from 0.01 to 8 mg per kg body weight of the patient. Each dosage unit may conveniently contain 0.1 to 1000 mg of the active substance, preferably it contains between 0.5 to 500 mg of the active substance.
The actual therapeutically effective amount or therapeutic dosage will of course depend on factors known by those skilled in the art such as age and weight of the patient, route of administration and severity of disease. In any case the combination will be administered at dosages and in a manner which allows a therapeutically effective amount to be delivered based upon patient's unique condition.
Suitable preparations for administering the compounds of formula (I) will be apparent to those with ordinary skill in the art and include for example tablets, pills, capsules, suppositories, lozenges, troches, solutions, syrups, elixirs, sachets, injectables, inhalatives and powders etc. The content of the pharmaceutically active compound(s) is advantageously in the range from 0.1 to 90 wt.-%, for example from 1 to 70 wt.-% of the composition as a whole.
Suitable tablets may be obtained, for example, by mixing one or more compounds according to formula (I) with known excipients, for example inert diluents, carriers, disintegrants, adjuvants, surfactants, binders and/or lubricants. The tablets may also consist of several layers.
The compounds of the invention may further be combined with one or more, preferably one additional therapeutic agent. According to one embodiment the additional therapeutic agent is selected from the group of therapeutic agents useful in the treatment of diseases or conditions associated with metabolic diseases or conditions such as for example diabetes mellitus, obesity, diabetic complications, hypertension, hyperlipidemia.
Therefore a compound of the invention may be combined with one or more additional therapeutic agents selected from the group consisting of anti-obesity agents (including appetite suppressants), agents which lower blood glucose, anti-diabetic agents, agents for treating dyslipidemias, such as lipid lowering agents, anti-hypertensive agents, antiatherosclerotic agents, anti-inflammatory active ingredients, agents for the treatment of malignant tumors, antithrombotic agents, agents for the treatment of heart failure and agents for the treatment of complications caused by diabetes or associated with diabetes.
Suitable anti-obesity agents include 11beta-hydroxy steroid dehydrogenase-1 (11beta-HSD type 1) inhibitors, stearoyl-CoA desaturase-1 (SCD-1) inhibitors, MCR-4 agonists, cholecystokinin-A (CCK-A) agonists, monoamine reuptake inhibitors, sympathomimetic agents, beta3 adrenergic agonists, dopamine agonists, melanocyte-stimulating hormone analogs, 5HT2c agonists, melanin concentrating hormone antagonists, leptin (the OB protein), leptin analogs, leptin agonists, galanin antagonists, lipase inhibitors, anorectic agents, neuropeptide-γ antagonists (e.g., NPY Y5 antagonists), PYY3-36 (including analogs thereof), thyromimetic agents, dehydroepiandrosterone or an analog thereof, glucocorticoid agonists or antagonists, orexin antagonists, glucagon-like peptide-1 agonists, ciliary neurotrophic factors, human agouti-related protein (AGRP) inhibitors, ghrelin antagonists, GOAT (Ghrelin O-Acyltransferase) inhibitors, histamine 3 antagonists or inverse agonists, neuromedin U agonists, MTP/ApoB inhibitors (e.g., gut-selective MTP inhibitors), opioid antagonists, orexin antagonists, and the like.
Preferred anti-obesity agents for use in the combination aspects of the present invention include gut-selective MTP inhibitors CCKa agonists, 5HT2c agonists, MCR4 agonists, lipase inhibitors, opioid antagonists, oleoyl-estrone, obinepitide, pramlintide (Symlin®), tesofensine (NS2330), leptin, liraglutide, bromocriptine, orlistat, exenatide (Byetta®), AOD-9604 (CAS No. 221231-10-3) and sibutramine.
Suitable anti-diabetic agents include sodium-glucose co-transporter (SGLT) inhibitors, 11beta-hydroxy steroid dehydrogenase-1 (11beta-HSD type 1) inhibitors, phosphodiesterase (PDE) 10 inhibitors, diacylglycerol acyltransferase (DGAT) 1 or 2 inhibitors, sulfonylureas (e.g., acetohexamide, chiorpropamide, diabinese, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, and tolbutamide), meglitinides, an alpha-amylase inhibitors (e.g., tendamistat, trestatin and AL-3688), alpha-glucoside hydrolase inhibitors (e.g., acarbose), alpha-glucosidase inhibitors (e.g., adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, and salbostatin), PPAR gamma agonists (e.g., balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, rosiglitazone and troglitazone), PPAR alpha/gamma agonists (e.g., CLX-0940, GW-1536, GW-20 1929, GW-2433, KRP-297, L-796449, LR-90, MK-0767 and SB-219994), biguanides (e.g., metformin), GLP-1 derivatives, glucagon-like peptide 1 (GLP-1) agonists (e.g., Byetta™, exendin-3 and exendin-4), GLP-1 receptor and glucagon receptor co-agonists, glucagon receptor antagonists, GIP receptor antagonists, protein tyrosine phosphatase-1 B (PTP-1 B) inhibitors (e.g., trodusquemine, hyrtiosal extract), SIRT-1 activators (e.g. reservatrol), dipeptidyl peptidease IV (DPP-IV) inhibitors (e.g., sitagliptin, vildagliptin, alogliptin, linagliptin and saxagliptin), insulin secretagogues, GPR119 agonists, GPR40 agonists, TGR5 agonists, MNK2 inhibitors, GOAT (Ghrelin O-Acyltransferase) inhibitors, fatty acid oxidation inhibitors, A2 antagonists, c-jun amino-terminal kinase (JNK) inhibitors, insulins, insulin derivatives, fast acting insulins, inhalable insulins, oral insulins, insulin mimetics, glycogen phosphorylase inhibitors, VPAC2 receptor agonists and glucokinase activators.
Preferred anti-diabetic agents are metformin, glucagon-like peptide 1 (GLP-1) agonists (e.g., Byetta™), GLP-1 receptor and glucagon receptor co-agonists, sodium-glucose co-transporter (SGLT) inhibitors, 11beta-hydroxy steroid dehydrogenase-1 (11beta-HSD type 1) inhibitors and DPP-IV inhibitors (e.g. sitagliptin, vildagliptin, alogliptin, linagliptin and saxagliptin).
Preferably, compounds of the present invention and/or pharmaceutical compositions comprising a compound of the present invention optionally in combination with one or more additional therapeutic agents are administered in conjunction with exercise and/or a diet.
Therefore, in another aspect, this invention relates to the use of a compound according to the invention in combination with one or more additional therapeutic agents described hereinbefore and hereinafter for the treatment or prevention of diseases or conditions which may be affected or which are mediated by the inhibition of the acetyl-CoA carboxylase(s), in particular ACC2, in particular diseases or conditions as described hereinbefore and hereinafter.
In yet another aspect the present invention relates a method for treating, including preventing a disease or condition mediated by the inhibition of acetyl-CoA carboxylase(s) in a patient that includes the step of administering to the patient, preferably a human, in need of such treatment a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of one or more additional therapeutic agents described in hereinbefore and hereinafter,
The use of the compound according to the invention in combination with the additional therapeutic agent may take place simultaneously or at staggered times.
The compound according to the invention and the one or more additional therapeutic agents may both be present together in one formulation, for example a tablet or capsule, or separately in two identical or different formulations, for example as a so-called kit-of-parts.
Consequently, in another aspect, this invention relates to a pharmaceutical composition which comprises a compound according to the invention and one or more additional therapeutic agents described hereinbefore and hereinafter, optionally together with one or more inert carriers and/or diluents.
Further aspects of the invention include the use of a compound according to the invention or a salt thereof as a crop protection agent to combat and/or prevent fungal infestations, or to control other pests such as weeds, insects, or acarids that are harmful to crops. Another aspect of the invention relates to the use of a compound according to the invention or a salt thereof for controlling and/or preventing plant pathogenic microorganisms, for example plant pathogenic fungi. Therefore one aspect of the invention is a compound according to the formula (I) or a salt thereof for use as a fungicide, insecticide, acaricide and/or herbicide. Another aspect of the invention relates to an agricultural composition comprising a compound of the present invention together with one or more suitable carriers. Another aspect of the invention relates to an agricultural composition comprising a compound of the present invention in combination with at least one additional fungicide and/or systemically acquired resistance inducer together with one or more suitable carriers.
Compounds of general formula (I) may be prepared by palladium-mediated Buchwald reactions or copper-mediated Ullmann reactions of pyrimidines (Py; II), that are substituted with 1-3 R1, with pyrrolidines (III) wherein Z is a leaving group and for example denotes Cl, Br or I.
Compounds of general formula (I) may be prepared by amide coupling reactions of amines (IV) with carboxylic acids (V) mediated by coupling reagents such as for example 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborat (TBTU), 1-chloro-N,N-2-trimethylpropenylamine, benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate and 2-chloro-1,3-dimethyl-2-imidazolinium hexafluorophosphate.
Alternatively, compounds of general formula (I) may be prepared by amide coupling reactions of amines (IV) with carboxylic acids chlorides (VI) or carboxylic acid anhydrides (VII).
Compounds of general formula (VIII) may be prepared by alkylation reactions of aromatic alcohols (IX) with electrophiles (X) wherein Z is a leaving group which for example denotes Cl, Br, I, mesylate, tosylate or triflate and RHetAryl is heteroaryl such as for example pyridinyl.
Compounds of general formula (XI) may be prepared by urea forming reactions such as reaction of amines (IV) with amines (XII) after reaction with reagents such as N,N-carbonylditriazole (CDT) or N,N-carbonyldiimidazole (CDI).
Compounds of general formula (XIII) may be prepared by urethane forming reactions such as reaction of amines (IV) with alcohols (XIV), wherein R8 is (C1-4-alkyl) which is optionally substituted with C3-7-cycloalkyl, after reaction with reagents such as CDT or CDI. Alcohols may be used in their deprotonated form.
Alternatively, compounds of general formula (XIII) may be prepared by urethane forming reactions such as reaction of amines (IV) with chloro formates (XV).
Compounds of general formula (I) may alternatively be prepared by nucleophilic aromatic substitution reactions (SNAr) of pyrimidyl halides (XVI) with pyrrolidines (III), wherein Z is a leaving group which for example denotes F, Cl, Br, I.
Compounds of general formula (XVII) may be prepared by aromatic subtitution of pyrimidyl halides (XVIII) with amines (XII) wherein Z is a leaving group which for example denotes F or Cl, Br, I.
Compounds of general formula (XIX) may be prepared by aromatic substitution of pyrimidyl halides (XVIII) with alcohols (XIV) wherein Z is a leaving group which for example denotes F or Cl, Br, I. Alcohols are used in their deprotonated form.
Compounds of general formula (XX) wherein Ar is aryl may be prepared by palladium-mediated Suzuki reactions of pyrimidine halides (XVIII) with boronic acids (XXI) or corresponding boronic esters wherein Z is a leaving group which for example denotes Cl, Br or I.
Compounds of general formula (XXII) may be prepared by acetylations such as reaction of amines (XXIII) with carboxylic acids chlorides (VI).
The Examples that follow are intended to illustrate the present invention without restricting it. The terms “ambient temperature” and “room temperature” are used interchangeably and designate a temperature of about 20° C.
As a rule, 1H-NMR and/or mass spectra have been obtained for the compounds prepared. The Rf values are determined using silica gel plates and UV light at 254 nm.
To describe the relative configuration of stereogenic centers straight bars are used. To describe the relative and absolute configuration, the bars have a wedged shape.
realtiv configuration:
relative and absolute configuration:
To 200 g (1.00 mol) (S)-1-(4-bromophenyl)ethylamine in 800 mL DCM are slowly added 94.5 mL (1.00 mol) acetic anhydride while cooling the mixture to 20-30° C. Then the cooling is removed and the reaction mixture is stirred at r.t. over night. Afterwards the mixture is consecutively washed with water, sat. aq. NaHCO3 solution, water, diluted aq. citric acid solution and again water. The org. layer is dried over MgSO4, filtered and the solvent is removed in vacuo. The crude product is used without further purification.
C10H12BrNO (M=242.1 g/mol)
ESI-MS: 242/244 [M+H]+
Rt (HPLC): 1.67 min (method A)
To 150 g (735 mmol) (S)-1-(4-bromophenyl)ethylamine in 2 L DCM are added 459 mL (918 mmol) of an aq. Na2CO3 solution (c=2 mol/L). To this mixture a solution of 164 g (749 mmol) BOC2O in 350 mL THF is added dropwise at r.t. and stirring is continued for 1 h. Then the mixture is poured onto water and stirred for additional 20 min. The layers are separated, the org. layer is washed with water (2×), dried over Na2SO4, filtered and the solvent is removed in vacuo.
C13H18BrNO2 (M=300.2 g/mol)
ESI-MS: 300/302 [M+H]+
Rt (TLC): 0.90 (silica gel, DCM/MeOH 9/1)
a) To a mixture of 60.0 g (248 mmol) of example I, 73.0 g (743 mmol) KOAc, 94.4 g (372 mmol) bis(pinakolato)diboron and 3.62 g (4.96 mmol) PdCl2(dppf) in an atmosphere of argon are added 450 mL DMSO and the resulting mixture is degassed twice and stirred at 80° C. for 3 h. Then the reaction mixture is cooled down to r.t., diluted with water and EtOAc and the layers are separated. The aq. layer is extracted with EtOAc (2×). The org. layers are combined, washed with water (3×), dried over MgSO4, filtered through a plug of Celite® and the solvent is removed in vacuo. The crude product is used without further purification.
C16H24BrNO3 (M=289.2 g/mol)
ESI-MS: 290 [M+H]+
Rt (HPLC): 1.19 min (method B)
b) 80.0 g (180 mmol) of the above mentioned product are added to 500 mL THF and cooled down to 0° C. 31.8 mL (360 mmol) H2O2 (35% in water) and subsequently 51.7 mL (155 mmol) 4
C10H13NO2 (M=179.2 g/mol)
ESI-MS: 180 [M+H]+
Rt (HPLC): 0.30 min (method C)
The following compounds are prepared analogously to example III.1
a) 10.0 g (66.1 mmol) (S)-4-methoxy-alpha-methylbenzylamine are added to 30 mL HBr (30% in AcOH) and stirred at 100° C. for 4 h. The reaction mixture is cooled to r.t. and the acid is removed in vacuo. The crude product is used without further purification.
b) 5.00 g (22.9 mmol) of the above mentioned product are added to 10 mL THF and 10 mL H2O before 13.5 g (160 mmol) NaHCO3 are added. Then 3.60 mL (25.2 mmol) benzyl chloroformate are added dropwise and the reaction mixture is stirred at r.t. for 3 h. Afterwards the reaction mixture is quenched by the addition of water and is set to a gentle acidic pH value with citric acid (10% in water). Then the product is extracted with EtOAc, the combined organic layers are dried over MgSO4, filtered and the solvent is removed in vacuo. The crude product is purified by flash chromatography (silica gel, PE/EtOAc).
C16H17NO3 (M=271.3 g/mol)
ESI-MS: 272 [M+H]+
Rt (HPLC): 1.65 min (method A)
6.00 g (22.6 mmol) 3-methanesulfonyloxy-pyrrolidine-1-carboxylic acid tert-butyl ester*, 6.14 g (22.6 mmol) of example IV and 14.7 g (45.2 mmol) Cs2CO3 are added to 80 mL DMF and stirred at 80° C. over night. The reaction mixture is filtered, washed with MeOH and the solvent is removed in vacuo. The crude product is purified by HPLC (MeOH/H2O/NH3).
C25H32N2O5 (M=440.5 g/mol)
ESI-MS: 439 [M−H]−
Rt (HPLC): 1.22 min (method C) *A representative procedure for the preparation of N-protected 3-methylsulfonyloxypyrrolidines can be found in Zersh et al. Synthesis 2011, 22, 3669-3674
20.0 g (75.4 mmol) (S)-tert butyl 3-(methylsulfonyloxy)-pyrrolidine-1-carboxylate*, 13.5 g (75.4 mmol) of example III.1 and 49.1 g (151 mmol) Cs2CO3 are added to 150 mL DMF and stirred for 16 h at 80° C. Then the reaction mixture is cooled down to r.t., diluted with water and extracted with EtOAc (2×). The org. layers are combined, washed with aq. NaHCO3 solution (3×) and dried over MgSO4. After filtration the solvent is removed in vacuo and the crude product is purified by flash chromatography (silica gel, DCM/MeOH 93/7).
C19H28N2O4 (M=348.4 g/mol)
ESI-MS: 349 [M+H]+
Rt (HPLC): 1.02 min (method C)
The following compounds are prepared analogously to example VI.1
To 20.5 g (58.8 mmol) of example VI.1 in 200 mL dioxane are added 29.4 mL (118 mmol) HCl in dioxane (c=4 mol/L) and the resulting mixture is stirred at r.t. over night. Additional 15 mL (60 mmol) HCl in dioxane (c=4 mol/L) are added and stirring is continued for 1 d. Then the reaction mixture is treated with TBME and the precipitate is filtered, washed with TBME and dried at 40° C. in vacuo.
C14H20N2O2*HCl (M=284.8 g/mol)
ESI-MS: 249 [M+H]+
Rt (HPLC): 0.63 min (method C)
The following compounds are prepared analogously to example VII.1
For the examples VII.3 and VII.4 the resulting product is transferred into the free base using a NaOH solution (c=1 mol/L).
4.70 g (10.7 mmol) of example VI.3 in 25 mL dioxane are charged with 5.33 mL (21.3 mmol) of a HCl solution in dioxane (c=4 mol/L) and stirred at r.t. over night. The solvent is removed in vacuo and the residue is taken up in ethanol and the solvent is removed again. The resulting product is triturated with DIPE and dried at 50° C.
C20H24N2O3*HCl (M=376.9 g/mol)
ESI-MS: 324 [M+H−NH3]+
Rt (HPLC): 1.07 min (method C)
3.80 g (10.1 mmol) of example VIII in 20 mL DMF are charged with 5.15 mL (29.9 mmol) DIPEA, 3.80 g (11.5 mmol) TBTU and finally after 10 min with 1.29 g (9.99 mmol) thiazole-5-carboxylic acid. The reaction mixture is stirred at r.t. over night. The next day water is added and the mixture is extracted with EtOAc (3×). The organic layers are combined, dried over MgSO4, filtered and the solvent is removed in vacuo. The crude product is purified by flash chromatography (silica gel, EtOAc). Then the product is added to EtOAc and washed with a saturated aq. NaHCO3 solution (3×), dried over MgSO4, filtered and the solvent is removed in vacuo.
C24H25N3O4S (M=451.5 g/mol)
ESI-MS: 452 [M+H]+
Rt (HPLC): 0.92 min (method D)
The following compounds are prepared analogously to example IX.1
For the examples IX.2 the reaction is stirred for 4 h and a preciptate is formed. The solvent is reduced in vacuo and the residue suspended in water, filtered, washed with tert-butyl methylether and dried at 40° C. in an oven with recirculating air.
15.0 g (34.1 mmol) of example VI.3 in 200 mL methanol are hydrogenated at r.t. using 1.50 g Pd/C (10%) and a hydrogen pressure of 3 bar. After completion the reaction mixture is filtered and the solvent is removed in vacuo.
C17H26N2O3 (M=306.4 g/mol)
ESI-MS: 307 [M+H]+
Rt (HPLC): 1.01 min (method C)
2.30 g (5.09 mmol) of example IX in 70 mL ACN are charged with 3.68 mL (25.7 mmol) iodotrimethylsilane and stirred at r.t. for 1 h. The reaction is quenched by the addition of some water. Solvent is removed in vacuo and the crude product is purified by HPLC (ACN/H2O/FA).
C16H19N3O2S (M=317.4 g/mol)
ESI-MS: 318 [M+H]+
Rt (HPLC): 0.69 min (method D)
The following compounds are prepared analogously to example XI.1
0.80 mg (6.13 mmol) 2-chloro-5-hydroxypyrimidine, 1.26 g (9.19 mmol) 1-bromo-2-methylpropane and 1.69 g (12.26 mmol) K2CO3 are added to 10 mL DMF and stirred at 80° C. over night. Afterwards the reaction is quenched by the addition of water and extracted with EtOAc. The org. layers are combined, dried over MgSO4, filtered and the solvent is removed in vacuo.
C8H11ClN2O (M=186.6 g/mol)
ESI-MS: 187 [M+H]+
Rt (HPLC): 1.04 min (method D)
The following compounds are prepared analogously to example XII.1.
For example XII.4 the reaction conditions are 100° C. for 30 min.
0.55 mL (5.99 mmol) cyclopropane methanol in 15 mL THF are charged with 0.31 g (7.19 mmol) NaH and the reaction mixture is stirred at r.t. for 10 min. Then 1.00 g (5.99 mmol) 4,6-dichloro-5-fluoro-pyrimidine are added and stirred at r.t. for 1 h. Afterwards the reaction is quenched by the addition of water and extracted with EtOAc. The organic layers are combined, washed with water (2×), dried over MgSO4, filtered and the solvent is removed in vacuo.
C8H8ClFN2O (M=202.6 g/mol)
ESI-MS: 203 [M+H]+
Rf (TLC): 0.37 (silica gel, PE/EtOAc 9/1)
The following compounds are prepared analogously to example XIII.1.
For example XIII.2 KOtBu is used as base and added portionwise at 0° C. to the alcohol. The mixture is added at 0° C. to the corresponding pyrimidine in THF.
a) To 1.00 g (8.19 mmol) tert-butylmalononitroletrade in 6 mL toluene are added 16 mL (240 mmol) di-iso-butylammoniumhydride (c=1.5 mol/L in toluene) at −60° C. Cooling is removed and the reaction mixture is stirred at r.t. for 4 h. The reaction is quenched by the addition of 1
C7H12O2 (M=128.2 g/mol)
ESI-MS: 129 [M+H]+
Rt (HPLC): n.d.
b) Under inert gas atmosphere to 1 mL HCl (C=10 mol/L) are added to 225 mg (3.75 mmol) urea in 10 mL EtOH and stirred at r.t. for 10 min. Then 400 mg (3.12 mmol) of the above mentioned product are added and the resulting mixture is stirred at reflux for 40 h. The reaction is quenched by the addition of water and extracted with DCM. The aq. layer is basified with NaOH to pH 8 and extracted with DCM. Then the combined org. layers are dried over Na2SO4, filtered and the solvent is removed in vacuo. The crude product is used without further purification.
c) 300 mg (1.97 mmol) of the above mentioned product and 9 mL POCl3 are stirred at 160° C. for 3 h. The solvent is removed in vacuo and the residue is treated with water and basified with aq NaOH solution (c=3 mol/L) to pH 10. The resulting mixture is extracted with DCM and dried over Na2SO4, filtered and the solvent is removed in vacuo. The crude product is purified by flash chromatography (silica gel, DCM/MeOH 98/2).
C8H11ClN2 (M=170.6 g/mol)
ESI-MS: 171 [m+H]+
a) To 1.00 g (7.14 mmol) ethyl 4-pyrazolecarboxylate and 0.98 mL (10.7 mml) 3,4-dihydro-2H-pyran an 20 mL THF are added 0.94 mL (12.1 mmol) TFA and the reaction mixture is stirred at 80° C. over night. Afterwards the reaction mixture is diluted with DCM and charged with aq. NaHCO3 solution. The layers are separated and the org. layer is dried over MgSO4, filtered and the solvent is removed in vacuo.
C11H16N2O3 (M=224.3 g/mol)
ESI-MS: 247 [M+Na]+
Rt (HPLC): 1.23 min (method M)
b) To 1.67 g (7.45 mmol) of the above mentioned product in 10 mL EtOH 11.2 mL (11.2 mmol) NaOH solution (c=1 mol/L) is added and stirred at r.t. for 4 h. Then the organic solvent is removed in vacuo and the residue is acidified with citric acid (c=1 mol/L) and extracted with EtOAc (2×). The combined org. layers are dried over MgSO4, filtered and the solvent is removed in vacuo.
C9H12N2O3 (M=196.2 g/mol)
ESI-MS: 195 [M−H]−
Rt (HPLC): 0.60 min (method D)
1.00 g (3.51 mmol) of example VII.1, 0.52 g (3.51 mmol) 2,4-dichloropyrimidine and 0.99 mL (7.02 mmol) TEA are added to 10 mL THF and stirred at 80° C. for 2 h. The reaction mixture is diluted with diethylether. The precipitate is filtered and dried.
C18H21ClN4O2 (M=360.8 g/mol)
ESI-MS: 361 [M+H]+
Rt (HPLC): 1.06 min (method G)
The following compounds are prepared analogously to example XVI.1
For the examples XVI.2, XVI.3 and XVI.15 the reaction conditions are r.t. over night.
For the examples XVI.4, XVI.7, XVI.9, XVI.10, XVI.11, the reaction time is over night.
For the examples XVI.5, XVI.6, XVI.12, XVI.13 ACN is used as solvent, K2CO3 as base and the reaction conditions are r.t. between 3 h and over night.
For example XVI.8 DCM is used as solvent and the reaction conditions are 0° C. for 1 h.
For the example XVI.17, XVI.19 and XVI.21 the reaction mixture is stirred at r.t. over night, diluted with water and extracted with EtOAc. The org. layers are combined, dried over MgSO4, filtered and the solvent is removed in vacuo.
For the example XVI.18/20 the reaction conditions are 4 h at 50° C. The reaction is directly purified by HPLC.
To 1.10 g (2.63 mmol) of product XVI.2 and 0.91 mL (5.25 mmol) DIPEA in 20 mL EtOH are added 0.45 mL (5.25 mmol) N-ethylmethylamine and stirred at 80° C. for 4 d. Afterwards the reaction mixture is quenched by the addition of water and extracted with DCM (2×). The combined org. layers are dried over MgSO4, filtered and the solvent is removed in vacuo.
C24H35N5O3 (M=441.6 g/mol)
ESI-MS: 442 [M+H]+
Rt (HPLC): 1.19 min (method E)
The following compounds are prepared analogously to example XVII.1.
For example XVII.3 the reaction time is 5 h.
80.0 mg (0.89 mmol) 2-methyl-propane-1,2-diol is added to 10 mL THF and charged with 40.0 mg (0.92 mmol) NaH. After 10 min at r.t., 250 mg (0.57 mmol) of example XVI.17 are added and the mixture is stirred at reflux over night. Then water and EtOAc are added and the layers are separated. The organic layer is washed with water (2×), dried over MgSO4, filtered and the solvent is removed in vacuo. The residue is triturated with DIPE.
C25H35FN4O5 (M=490.6 g/mol)
ESI-MS: 491 [M+H]+
Rt (HPLC): 1.10 min (method I
The following compound is prepared analogously to example XVIII.1.
For example XVIII.2 dioxane is used as solvent and the reaction conditions are 2.5 h at 80° C.
To 130 mg (0.27 mmol) of example XVIII are added 10 mL of an ethanolic HCl solution (c=1.3 mol/L). The resulting mixture is stirred at r.t. over night. The solvent is removed in vacuo.
C20H27FN4O3*HCl (M=426.9 g/mol)
ESI-MS: 391 [M+H]+
Rt (HPLC): 0.82 min (method I)
The following compounds are prepared analogously to example XIX.1
For the examples XIX.2-XI5 the starting material is added to dioxane and charged with an HCl solution in dioxane (c=4 mol/L). After removing of the solvent, the residue is triturated with TBME.
To 400 mg (0.85 mmol) of example XVI.3 in 10 mL DCM are added 25.6 mg (0.54 mmol) 2,6-lutidine and 254 mg (1.27 mmol) TMS-I and stirred at r.t. for 30 min. Then the reaction mixture is poured onto diluted aq. NaHCO3 solution and extracted with DCM. The combined org. layers are dried over MgSO4, filtered and the solvent is removed in vacuo.
C20H25FN4O2 (M=372.4 g/mol)
ESI-MS: 373 [M+H]+
Rt (HPLC): 0.95 min (method H)
The following compound is prepared analogously to example XX.1 For example XX.2 the reaction starts without 2,6-lutidine and the solvent is ACN. The starting materials combined under icecooling. The reaction mixture is quenched with MeOH then extracted with NaHCO3 solution and EE.
a) 141 mg (0.62 mmol) (+)-(1S,3R)—N-BoC-3-aminocyclopentanecarboxylic acid, 32.3 μl (1.85 mmol) DIPEA and 198 mg (0.62 mmol) TBTU are added to 5 mL DMF and stirred for 10 min. Then 230 mg (0.62 mmol) of the amine XX are added and the resulting mixture is stirred at r.t. over night. Afterwards the reaction is quenched by the addition of water and stirred at r.t. for 30 min. Then the precipitation is filtered, washed with water and dried at 45° C.
C31H42FN5O5 (M=583.7 g/mol)
ESI-MS: 584 [M+H]+
Rt (HPLC): 1.20 min (method I)
b) To 200 mg (0.34 mmol) of the above mentioned product in 10 mL DCM are added 39.7 μL (0.34 mmol) 2,6-lutidine and 73.5 μL (0.51 mmol) TMSI and stirred at r.t. for 30 min. Then the reaction mixture is poured into aq. NaHCO3 solution and extracted with DCM. The combined org. layers are dried over MgSO4, filtered and the solvent is removed in vacuo.
C26H34FN5O3 (M=483.6 g/mol)
ESI-MS: 484 [M+H]+
Rt (HPLC): 1.21 min (method E)
600 mg (2.11 mmol) of example VII.1, 275 mg (2.11 mmol) 2-chloro-5-hydroxypyrimidine and 1.12 mL (6.53 mmol) DIPEA in 8 mL NMP are stirred at 150° C. for 6 h in a microwave oven. Afterwards the reaction mixture is directly purified by HPLC (MeOH/H2O/NH3).
C18H22N4O3 (M=342.4 g/mol)
ESI-MS: 343 [M+H]+
Rt (HPLC): 1.04 min (method J)
The following compound is prepared analogously to example XXII.1
13.4 g (84.7 mmol) of 2-amino-4-methyl-thiazole-5-carboxylic acid, 35.8 ml (297 mmol) propionic acid anhydride in 90 ml propionic acid are stirred at 100° C. over night. The reaction is cooled to r.t. Then the mixture is poured into water (200 ml). A precipitate is formed, filtered and washed with water. Then the filtrate is suspended in water and stirred for 30 min. The precipitate is filtered again and dried at 50° C. in an oven with recirculating air.
C8H10N2O3S (M=214.2 g/mol)
ESI-MS: 215 [M+H]+
Rt (HPLC): 0.68 min (method I)
500 mg (1.14 mmol) of example XVI.21 and 330 mg (3.4 mmol) 6-azaspiro[2.4]-heptane are dissolved in NMP. The reaction is heated at 100° C. over night. The reaction is cooled to r.t. and diluted with water. The precipitate is filtered off and dried at 40° C.
C27H36FN5O3 (M=497.60 g/mol)
ESI-MS: 498[M+H]+
Rt (HPLC): 1.04 min (method I)
To 2 g (11.8 mmol) ethyl 2-amino-4-methyl-oxazole-5-carboxylate in 50 ml DCM are added 6.1 ml (35.3 mmol) DIPEA. To this mixture 0.92 ml (12.9 mmol) acetyl chloride are added and the reaction mixture is stirred at r.t. for 2 h. The mixture is diluted with further DCM and washed with water. The organic layer is separated, dried and the solvent is removed in vacuo.
C9H12N2O4 (M=212.08 g/mol)
The product was used without further characterization.
1.7 g (8.01 mmol) of Example XXV is dissolved in 10 ml ethanol. 5 ml of 2
C7H8N2O4 (M=184.05 g/mol)
A mixture of 1 g (6.41 mmol) ethyl 2-aminooxazole-4-carboxylate and 9.1 ml (96.3 mmol) acetic acid anhydride are stirred at r.t. over night. The solvent is removed in vacuo. Toluene is added and evaporated. This procedure is repeated three times. C8H10N2O4 (M=198.06 g/mol)
ESI-MS: 199[M+H]+
1.3 g (6.6 mmol) of Example XXVII are dissolved in 33 ml ethanol. 0.554 g (13.2 mmol) lithium hydroxide monohydrate are added and the reaction is stirred at r.t. over night. The solvent was evaportated and the residue is acidified with HCl. The resulting precipitate is filtrated, washed with cool water and dried.
C6H6N2O4 (M=170.03 g/mol)
ESI-MS: 171[M+H]+
a) 33 g (0.27 mol) 2,2-Difluorocyclopropanecarboxylic acid are added to 250 mL acetonitrile and charged with 40 mL (0.27 mol) (R)-1-(4-methoxyphenyl)ethylamine. After stirring at r.t. over night the precipitate is filtered off and recrystallised (3×) with ACN. The precipitate is added to 150 mL DCM, charged with 100 mL aq. HCl solution (c=1 mol/L) and extracted. The aq. layer is extracted three times with DCM, the organic layers are combined, dried over Na2SO4, filtered and the solvent is removed in vacuo.
C4H4F2O2 (M=122.1 g/mol)
ESI-MS: 121 [M−H]−
Rt (GC): 26.1 min (method a)
b) 7.2 g (59 mmol) R-2,2-difluoro-cyclopropanecarboxylic acid are added to 100 mL THF, chilled to 0° C. and 35 mL (77 mmol) lithium aluminum hydride solution (2.2 M in 2-methyltetrahydrofuran) are added dropwise. The mixture is stirred at r.t. over night. After that the mixture is chilled to 0° C. and quenched by the addition of 3 ml water and 3 ml aq. NaOH solution (c=4 mol/L) slowly. The resulting mixture is stirred for 30 min, filtered, washed with THF and the filtrate is concentrated by evaporation. The residue is added to Et2O, dried over Na2SO4, filtered and the solvent is removed in vacuo.
C4H4F2O (M=108.1 g/mol)
Rt (GC): 15.4 min (method a)
c) 2.16 g (20.0 mmol) of the above mentioned product, 2.75 g (20 mmol) 1-chloro-5-hydroxypyrimidine and 6.56 g (25 mmol) triphenylphosphine are added to 20 ml THF and cooled to 0° C. Then 11.5 mL (25 mmol) diethylazocarboxylate (40% in toluene) are added carefully at constant temperature. Then cooling is removed and the mixture is stirred at r.t. for 3 h. Afterwards the solvent is removed in vacuo, diethylether is added and the mixture is filtered. The solvent is removed in vacuo and the residue is purified by flash chromatography (silica gel, PE/EtOAc)
C8H7ClF2N2O (M=220.60 g/mol)
ESI-MS: 221 [M+H]+
Rt (HPLC): 0.91 min (method I)
To 60.0 mg (0.21 mmol) of the product VII.1 in 2 mL dioxane are added 48.1 mg (0.21 mmol) 5-bromo-2-(cyclobutylamino)-pyrimidine, 83.5 mg (0.84 mmol) NaOtBu, 25.1 mg (0.08 mmol) 2-(di-tert-butylphosphino)biphenyl and 19.3 mg (0.02 mmol) Pd2(dba)3. The mixture is degassed thoroughly and stirred at 45° C. over night. To the reaction mixture a small amount of water is added, the mixture is filtered and afterwards directly purified by HPLC (MeOH/H2O/NH3).
To 60.0 mg (0.21 mmol) of the product VII.1 in 2 mL dioxane are added 48.1 mg (0.21 mmol) 5-bromo-2-(cyclobutylamino)-pyrimidine, 83.5 mg (0.84 mmol) NaOtBu and 31.0 mg (0.04 mmol) chloro(2-dicyclohexyl-phosphino-2′,4′,6′-tri-iso-propyl-1,1′-biphenyl)(2-(2-aminoethyl)-phenyl)-palladium (II). The mixture is degassed thoroughly and stirred at 45° C. for 3 h. A small amount of water and MeOH are added, the mixture is filtered and afterwards purified by HPLC (MeOH/H2O/TFA).
C22H29N5O2 (M=395.5 g/mol)
ESI-MS: 396 [M+H]+
Rt (HPLC): 1.00 min (method C)
The following compounds are prepared analogously to example 1.1.
For example 1.2 the reaction conditions are 80° C. for 1 h.
14.6 mg (0.17 mmol) cyclopropanecarboxylic acid, 88.4 μl (0.51 mmol) DIPEA and 54.3 mg (0.17 mmol) TBTU are added to 3 mL DMF and stirred for 10 min. Then 70.0 mg (0.17 mmol) of the amine XIX.3 are added and the resulting mixture is stirred at r.t. over night. Afterwards the mixture is directly purified by HPLC (ACN/H2O/TFA).
C23H29F2N5O2 (M=445.5 g/mol)
ESI-MS: 446 [M+H]+
Rt (HPLC): 0.99 min (method E)
The following compounds are prepared analogously to example 2.1, using the appropriate carboxylic acid: For the examples 2.7, 2.15 and 2.17 the intermediate is added in methanol and the final product is treated with aq. HCl solution (c=1 mol/L) to cleave the THP protecting group.
For the examples where 1-chloro-N,N-2-trimethylpropenylamine is used, the reagent is added to the mixture of the appropriate acid in DCM and stirred at r.t. for 30 min.
For the examples 2.8-2.11, 2.13-2.14 and 2.16 the reaction time is 1 h.
For the examples 2.26-2.28 TEA is used as base.
For the examples 2.25-2.34 THF is used as solvent
To 0.17 mmol of the appropriate 1-phenethylamine and 0.42 mmol TEA in 3 mL DCM are added to 0.19 mmol CDT and stirred for at r.t. 10 min. Then 0.51 mmol of the other amine are added and the resulting mixture is stirred at r.t over night. Afterwards some DMF is added and the mixture is directly purified by HPLC (ACN/H2O/TFA).
C22H30F2N6O2 (M=448.5 g/mol)
ESI-MS: 449 [M+H]+
Rt (HPLC): 0.97 min (method E)
To 0.34 mmol of the appropriate heteroaniline in 3 mL dioxane are added 0.34 mmol CDT and 0.34 mmol DBU and the resulting mixture is stirred at r.t. for 1 h. Then 0.17 mmol of the appropriate 1-phenethylamine are added and stirring is continued over night. The mixture is purified by HPLC (ACN/H2O/NH3).
To 0.17 mmol of the appropriate 1-phenethylamine in 2 mL THF and 0.43 mmol DIPEA are added 0.20 mmol dimethylcarbamoyl chloride and the resulting mixture is stirred for 1 h at r.t. The mixture is filtered and directly purified by HPLC (ACN/H2O/TFA).
The appropriate isocyante is used instead of the appropriate carbamoyl chloride.
The following compounds are prepared analogously to example 3.1.
For the examples 3.3-3.5 and 3.7-3.9 the reaction conditions are 50° C. over night.
70.0 mg (0.17 mmol) of the amine XIX.3 in 2 mL ACN are cooled to 5° C. in an ice-water bath. Then 71.2 μL (0.51 mmol) TEA and 19.6 μL (0.25 mmol) methyl chloroformate are added and the resulting mixture is stirred at 5° C. for 2 h. The crude mixture is directly purified by HPLC (ACN/H2O/TFA).
C21H27F2N5O3 (M=435.5 g/mol)
ESI-MS: 436 [M+H]+
Rt (HPLC): 1.01 min (method E)
To 70.0 mg (0.17 mmol) of amine XIX.3 in 2 mL DCM are added 30.7 mg (0.19 mmol) CDT and 21.2 μL (0.18 mmol) TEA and stirred at r.t. for 1 h. Then 10.3 μL (0.19 mmol) methanol is added and stirred at 35° C. over night. The crude mixture is directly purified by HPLC (MeOH/H2O/NH3).
The following compounds are prepared analogously to example 4.1. For example 4.2 the reaction conditions are 50° C. over night.
For example 4.5 the reaction conditions are r.t. over night.
For example 4.6 the reaction is done in THF with DIPEA as base. The reaction conditions are r.t. for 1 h.
To 70.0 mg (0.19 mmol) of the amine XIX.2 and 96.8 μL (0.56 mmol) DIPEA in 3 mL THF are added 32.2 μL (0.19 mmol) difluoroacetic anhydride and the mixture is stirred at r.t. over night. The mixture is directly purified by HPLC (ACN/H2O/TFA).
C21H27F2N5O2 (M=419.5 g/mol)
ESI-MS: 420 [M+H]+
Rt (HPLC): 1.01 min (method E)
The following compounds are prepared analogously to example 5.1
80.0 mg (0.28 mmol) of the amine VII.1, 55.8 mg (0.28 mmol) of example XII.4 and 144 μL (0.84 mmol) DIPEA in 2 mL NMP are stirred at 100° C. for 30 min. The reaction mixture is directly purified by HPLC (ACN/H2O/NH3).
C23H30H4O3 (M=410.5 g/mol)
ESI-MS: 411 [M+H]+
Rt (HPLC): 0.93 min (method H)
The following compounds are prepared analogously to example 6.1.
For the examples 6.4-6.6 and 6.12-6.15 the reaction conditions are 35° C. over night.
For example 6.7 the reaction conditions are 150° C. over night.
For the examples 6.7-6.8 and 6.21 the reaction conditions are 120° C. for 1 h.
For the examples 6.9, 6.14-6.16 and 6.18 the reaction conditions are 70° C. over night.
For example 6.22 DMSO is used as solvent and the reaction conditions are 60° C. over night.
To 22.8 mg (0.32 mmol) cyclopropanemethanol in 2 mL THF are added 8.62 mg (0.35 mmol) NaH and stirred at r.t. for 10 min. Then 60.0 mg (0.16 mmol) of example XVI.10 are added and the resulting mixture is stirred at 80° C. over night. Afterwards the reaction mixture is filtered and directly purified by HPLC (MeOH/H2O/NH3).
C22H27FN4O3 (M=414.5 g/mol)
ESI-MS: 415 [m+H]+
Rt (HPLC): 1.14 min (method C)
The following compounds are prepared analogously to example 7.1.
For the examples 7.5-7.10 the reaction conditions are r.t. over night.
For example 7.13 DMSO is used as solvent and the reaction conditions are 50° C. over night.
For the examples 7.14-7.18, 7.26-7.35, 7.37-7.42, 7.45-7.47, 7.52-7.53, 7.57 the reaction conditions are 50° C. over night.
For the examples 7.20-7.25 DMSO is used as solvent and the reaction conditions are 80° C. for 1 h.
For the examples 7.45 and 7.48 example 7.5 is separated using chiral HPLC (column: Daicel Ciralpak® AYH (20×250 mm; 5 μm), 50% EtOH (with 0.2% diethylamine) 50% CO2, 150 bar, flow: 60 mL/min).
For the example 7.62, 7.66, 7.63 dioxane is used as solvent and the reaction conditions are 50° C. over night.
For the examples 7.65 dioxane is used as solvent and the reaction conditions are r.t. over night.
For the example 7.67 dioxane is used as solvent and the reaction conditions are 130° C. for 2 h
80.0 mg (0.21 mmol) of example XVI.5 and 28.6 mg (0.63 mmol) dimethylamine are added to 1 mL NMP and stirred at 120° C. over night. Afterwards the reaction mixture is directly purified by HPLC (MeOH/H2O/NH3).
C20H26FN5O2 (M=387.5 g/mol)
ESI-MS: 388 [M+H]+
Rt (HPLC): 1.08 min (method C)
The following compounds are prepared analogously to example 8.1.
For the examples 8.2-8.13, 8.15, 8.22, 8.23, 8.27, 8.30-8.32, 8.36-8.46, 8.57, 8.58, 8.61-8.62, 8.106-8.110 and 8.122-8.286, 8.291 DIPEA (3 eq) as base is added.
For the examples 8.14-8.25 the reaction conditions are 150° C. for 1 h in a microwave oven.
For the examples 8.33-8.35, 8.37-8.56, 8.60 and 8.62 the reaction conditions are 80° C. for 2 h.
For the examples 8.63-8.81, 8.83, 8.92-8.95, 8.308-8.311, 8.314 and 8.316 EtOH is used as solvent, DIPEA (1.5 eq) as base and the reaction conditions are 80° C. over night.
For the examples 8.84-8.91, 8.97-8.101 and 8.302-8.304 DIPEA (3 eq) is used as base and the reaction conditions are 200° C. for 3 h in a microwave oven.
For the examples 8.96 and 8.118-8.121 EtOH is used as solvent.
For the examples 8.102-8.105 and 8.111-8.117-Dioxan is used as solvent, DIPEA (3 eq) as base and the reaction conditions are 140° C. for 1 h in a microwave oven.
For the example 8.291 the product from the reaction (=example 8.269) was separated using chiral HPLC (Daicel Chiralpak® AS-H 20×250 mm, 5 μM, 60 mL/min, T=40° C., 120 bar, 30% MeOH (with 0.2% diethylamine) and 70% CO2) (Analytical detection with Daicel Chiralpak® AS-H, 250 mm×4.6 mm, 5μ, 4 mL/min, 30% MeOH (with 0.2% diethylamine), 70% CO2, Rt=2.29 min, as earlier eluting diastereomer).
For the example 8.292-8.300 and 8.305-8.307, 8.312, 8.315, 8.317-8.319 the reaction is done in dioxane at 100° C. in the presence of DIPEA as base.
For the example 8.301 the reaction is done in dioxane at 140° C. in the presence of DIPEA as base.
For the examples 8.320-8.321 sodium tert. butoxide is used as base, The reaction is done in Dioxan and stirred at 50° C. over night.
To 70.0 mg (0.19 mmol) of the product XVI.1 in 4 mL toluene are added 0.2 mL water, 5.93 mg (0.02 mmol) tricyclohexylphosphine, 144 mg (0.68 mmol) K3PO4 and 88.4 mg (0.58 mmol) 3-methoxyphenylboronic acid and the mixture is degassed thoroughly. Then 6.53 mg (0.03 mmol) palladium(II)acetate is added and the resulting mixture ist stirred at 100° C. over night. Afterwards the reaction mixture is filtered. A small amount of MeOH and DMF is added and the mixture is purified by HPLC (MeOH/H2O/NH3).
C25H28N4O3 (M=432.5 g/mol)
ESI-MS: 433 [M+H]+
Rt (HPLC): 0.97 min (method B)
The following compounds are prepared analogously to example 9.1. For example 9.2 the reaction is done in dioxane with PdCl2(dppf) as catalyst.
For the examples 9.3-9.4 the reaction is done in THF. The used catalyst is PdCl2(dppf) and the reaction conditions are 2.5 h at 60° C.
To 70.0 mg (0.15 mmol) of the amine XXI and 49.5 μL (0.29 mmol) DIPEA in 2 mL DCM are added 11.4 mg (0.15 mmol) acetyl chloride and the mixture is stirred at r.t. for 1 h. The resulting mixture is purified directly by HPLC (ACN/H2O/TFA).
C28H36FN5O4 (M=525.6 g/mol)
ESI-MS: 526 [M+H]+
Rt (HPLC): 1.34 min (method E)
The following compounds are prepared analogously to example 10.1.
For the examples 10.3-10.5 THF is used as solvent.
Method O
Type: GC 7890
Carrier gas: helium
Column: BGB-175; 50 m; 0.25 mm ID; 0.25 μm DF (30 m and 20 m column coupled)
Injector temperature: 220° C.
Flow: 5.0 ml/Min
Temperature program: 50° C., 0 min; 3° C./min to 160° C. 00 min hold
| Number | Date | Country | Kind |
|---|---|---|---|
| 13164172.2 | Apr 2013 | EP | regional |
